Patents by Inventor Dana Vaughn

Dana Vaughn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral Rapamycin Nanoparticle Preparations and Use
    Publication number: 20210386672
    Abstract: Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer, neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders. The embodiments discussed address the present need for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
    Type: Application
    Filed: August 2, 2021
    Publication date: December 16, 2021
    Applicant: Rapamycin Holdings, Inc.
    Inventors: Dana Vaughn, Neal K. Vail
  • Oral rapamycin nanoparticle preparations and use
    Patent number: 11077061
    Abstract: Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer, neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders. The embodiments discussed address the present need for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: August 3, 2021
    Assignee: Rapamycin Holdings, Inc.
    Inventors: Dana Vaughn, Neal K. Vail
  • Oral Rapamycin Nanoparticle Preparations and Use
    Publication number: 20190350856
    Abstract: Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer, neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders. The embodiments discussed address the present need for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
    Type: Application
    Filed: July 31, 2019
    Publication date: November 21, 2019
    Applicant: Rapamycin Holdings, Inc.
    Inventors: Dana Vaughn, Neal K. Vail